Literature DB >> 24102637

The impact of age on the diagnosis and therapy of myelodysplastic syndromes: results from a retrospective multicenter analysis in Germany.

Norbert Gattermann1, Andrea Kündgen, Lenka Kellermann, Matti Zeffel, Bernadette Paessens, Ulrich Germing.   

Abstract

Myelodysplastic syndromes (MDS) is a disease of predominantly elderly patients with a median age of >70 yrs. However, data on the management of these patients outside of clinical trials are scarce. To assess patterns of MDS management in routine patient care with regard to the impact of age, we conducted a multicenter, representative survey of MDS health services in Germany. Data of 269 patients treated at 57 institutions were collected from preplanned chart reviews and were analyzed retrospectively. At diagnosis, median age was 70 yrs, 50% of patients had a Karnofsky index (KI) of 90%, and 12% had a comorbidity index ≥ 3 according to Sorror et al. (J Clin Oncol, 25, 2007, 4246). Cytogenetic analysis and International Prognostic Scoring System (IPSS) risk assessment were performed significantly less frequently in patients >75 yrs than in patients ≤ 75 yrs (P < 0.001 and P = 0.019). In bivariate analysis, potential predictors for performing IPSS risk assessment were age ≤ 75 yrs (y/n, P = 0.019), diagnosis at a university hospital (y/n, P = 0.001), WHO subtypes RCUD (y/n, P = 0.028), RARS (y/n, P = 0.002), or RAEB II (y/n, P = 0.037). Patients ≤ 75 yrs were more likely to receive active therapies (i.e., chemotherapy, immunomodulatory therapy, or epigenetic therapy) than patients >75 yrs (51% vs. 37%, P = 0.007). In bivariate analysis age ≤ 75 yrs (y/n, P = 0.007) was a significant predictor for active treatment with no correlation with the other predictors [IPSS risk score int-2 or high (y/n, P = 0.005), WHO subtypes RCUD (y/n, P < 0.001), RCMD (y/n, P = 0.003), RAEB II (y/n, P < 0.001), or CMML I (y/n, P = 0.020)]. This survey confirms the impact of age on the thoroughness of MDS diagnosis and the decision for active treatment. As cytogenetic analysis and risk assessment are essential for the choice of appropriate therapy, elderly patients in particular may not be receiving adequate treatment.
© 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  diagnosis; elderly; myelodysplastic syndromes; prognosis; therapy

Mesh:

Year:  2013        PMID: 24102637     DOI: 10.1111/ejh.12196

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  6 in total

1.  Differences in community and academic practice patterns for newly diagnosed myelodysplastic syndromes (MDS) patients.

Authors:  Daniel F Pease; Julie A Ross; Jenny N Poynter; Phuong L Nguyen; Betsy Hirsch; Adina Cioc; Michelle A Roesler; Erica D Warlick
Journal:  Cancer Epidemiol       Date:  2015-02-18       Impact factor: 2.984

2.  Non-hematologic predictors of mortality improve the prognostic value of the international prognostic scoring system for MDS in older adults.

Authors:  K Rebecca Fega; Gregory A Abel; Gabriela Motyckova; Alexander E Sherman; Daniel J DeAngelo; David P Steensma; Ilene Galinsky; Martha Wadleigh; Richard M Stone; Jane A Driver
Journal:  J Geriatr Oncol       Date:  2015-06-11       Impact factor: 3.599

3.  Allogeneic stem cell transplantation in patients above 55: suggestion for a further stratification of the HCT-CI.

Authors:  Christian Späth; Christoph Busemann; William H Krüger
Journal:  J Cancer Res Clin Oncol       Date:  2014-06-26       Impact factor: 4.553

4.  Guideline-based indicators for adult patients with myelodysplastic syndromes.

Authors:  Kristina Stojkov; Tobias Silzle; Georg Stussi; David Schwappach; Juerg Bernhard; David Bowen; Jaroslav Čermák; Avinash G Dinmohamed; Corien Eeltink; Sabrina Eggmann; Pierre Fenaux; Ulrich Germing; Manuel Haschke; Eva Hellstrom-Lindberg; Monika Heger; Arjan A van de Loosdrecht; Jakob Passweg; Michael Pfeilstöcker; Uwe Platzbecker; Luca Malcovati; António Medina de Almeida; Moshe Mittelman; Christine Morgenthaler; David P Steensma; Valeria Santini; Reinhard Stauder; Argiris Symeonidis; Sämi Schär; Charlotte Maddox; Theo de Witte; Julia Bohlius; Nicolas Bonadies
Journal:  Blood Adv       Date:  2020-08-25

5.  Moving cancer care closer to home: a single-centre experience of home chemotherapy administration for patients with myelodysplastic syndrome.

Authors:  Vidhya Murthy; Jacqueline Wilson; Julie Suhr; Lydia James; Harley Tombs; Elmoamly Shereef; Emmanuel Nikolousis
Journal:  ESMO Open       Date:  2019-03-30

6.  The incidence, risk factors, and survival of acute myeloid leukemia secondary to myelodysplastic syndrome: A population-based study.

Authors:  Xingnong Ye; Dan Chen; Yan Zheng; Cai Wu; Xiaoqiong Zhu; Jian Huang
Journal:  Hematol Oncol       Date:  2019-09-06       Impact factor: 5.271

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.